Navigation Links
Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Date:4/1/2009

FARMINGDALE, N.Y., April 1 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Sophysa Benelux, based in Braine l'Alleud, Belgium, for the distribution of the SonaStar(TM) Ultrasonic Surgical Aspirator and the BoneScalpel(TM) Ultrasonic Bone Cutter.

The agreement provides Sophysa with the rights to sell in Belgium and Luxembourg, and includes minimum purchase requirements.

Sophysa is acknowledged as a market leader and has built a reputation as a distributor of state-of-the-art medical devices and capital equipment, with special emphasis in neuro and spine surgery.

The SonaStar is used by Neuro and General Surgeons for quick and efficient removal of both hard and soft tumors while sparing most vessels. In addition, OsteoSculpt(TM) bone shaving technology can be employed with the SonaStar to safely remove osseous structures, thus providing access to the surgical site.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument without the potential hazards associated with rotary sharps.

"Misonix welcomes Sophysa Benelux to our growing sales and distribution organization. We know Sophysa as a first tier distributor of advanced medical equipment in the Benelux countries," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Sophysa has established themselves as a quality distribution partner for successfully introducing high tech medical devices to their markets. We are particularly pleased that they will be distributing two of our product platforms through their well established channels."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Misonix Contact:                 Investor Relations Contact:
    Richard Zaremba                  Kevin McGrath / Cameron Associates, Inc.
    631-694-9555                     212-245-4577
    invest@misonix.com               Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Misonix Announces New Sales Agency Agreement for Eastern Europe
2. Misonix Announces New Distribution Agreement for Israel
3. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
4. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
5. Misonix Announces New HIFU Distribution Agreement for Italy
6. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
7. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
8. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
9. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
10. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
11. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... PORTLAND, Ore. (PRWEB) , ... February 11, 2016 ... ... found Medicaid coverage results in significantly higher rates of several common cancer screenings, ... early, resulting in better outcomes and survival rates. , The study,“What Does ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... known locally for a series of therapeutic sessions to help Los Angeles-area actors ... and in their lives. The series, known as “Mindfulness for Actors and Artists,” ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... 10, 2016 , ... Intermedix announced on Wednesday that it ... emergency medicine professional association, to support the organization's newly established physician group with ... Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their own ...
(Date:2/10/2016)... ... ... 10 Best Water is excited to announce a new monthly ... topped the list as a result of their commitment to offering clients creative, customized, ... 5100, a top notch water company that specializes in providing the public with refreshing ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  NanoViricides, Inc. (NYSE MKT: ... entered into an agreement with the University of ... candidates in standard animal models of ocular virus ... Director. Dr. Romanowski has extensive experience in ocular ... --> Eric Romanowski , Research Director. Dr. ...
(Date:2/11/2016)... 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... development of a once-daily, oral therapy for the treatment ... Officer, Dr. Maya Halpern , has notified the Company ... Officer and from its Board of Directors effective as ... age. Allen Baharaff . Mr. Baharaff continued, ...
(Date:2/11/2016)... Feb. 11, 2016 Indiso ltd , ... need of pulmonary and respiratory diseases announced today positive ... on COPD and asthma patients show improvements in respiratory ... --> --> Upper and lower respiratory ... the developed world and reached epidemic level. Increasing number ...
Breaking Medicine Technology: